Charles Schwab Investment Management Inc. Buys 202,863 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Charles Schwab Investment Management Inc. lifted its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 16.9% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,404,883 shares of the company's stock after purchasing an additional 202,863 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.45% of Amneal Pharmaceuticals worth $11,689,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in AMRX. Profund Advisors LLC increased its stake in shares of Amneal Pharmaceuticals by 8.1% in the 2nd quarter. Profund Advisors LLC now owns 22,522 shares of the company's stock worth $143,000 after acquiring an additional 1,680 shares in the last quarter. Rothschild Investment LLC purchased a new position in shares of Amneal Pharmaceuticals during the second quarter valued at approximately $26,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Amneal Pharmaceuticals by 13.3% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 34,952 shares of the company's stock valued at $222,000 after purchasing an additional 4,115 shares during the last quarter. Gladius Capital Management LP bought a new stake in shares of Amneal Pharmaceuticals in the 3rd quarter worth approximately $37,000. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Amneal Pharmaceuticals by 6.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 81,264 shares of the company's stock worth $493,000 after buying an additional 5,146 shares during the last quarter. 31.82% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Amneal Pharmaceuticals news, SVP Jason B. Daly sold 43,657 shares of the firm's stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $8.61, for a total value of $375,886.77. Following the transaction, the senior vice president now directly owns 13,665 shares of the company's stock, valued at approximately $117,655.65. This trade represents a 76.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 17.46% of the stock is owned by corporate insiders.

Amneal Pharmaceuticals Stock Down 4.3 %

AMRX traded down $0.36 during midday trading on Monday, hitting $8.09. 1,282,856 shares of the company traded hands, compared to its average volume of 1,394,864. The company's 50-day moving average is $8.54 and its 200 day moving average is $7.87. The firm has a market capitalization of $2.51 billion, a PE ratio of -11.90 and a beta of 1.12. Amneal Pharmaceuticals, Inc. has a 52 week low of $4.46 and a 52 week high of $9.48.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on AMRX shares. JPMorgan Chase & Co. raised Amneal Pharmaceuticals from an "underweight" rating to a "neutral" rating and set a $9.00 target price on the stock in a report on Friday, September 6th. Piper Sandler increased their price objective on shares of Amneal Pharmaceuticals from $9.00 to $11.00 and gave the company an "overweight" rating in a research report on Monday, November 11th. StockNews.com upgraded shares of Amneal Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Monday, November 11th. Truist Financial upped their target price on shares of Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a "buy" rating in a research note on Wednesday, October 2nd. Finally, Barclays raised their price target on shares of Amneal Pharmaceuticals from $8.00 to $10.00 and gave the company an "overweight" rating in a research report on Tuesday, August 13th. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $10.00.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.